Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M

RHYTHM PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$2.89 revenue$55,045,000

Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.
Net loss attributable to common stockholders improved to ($33.6M) or ($0.55)/share from ($46.7M) ($0.82)/share.
Cash balance $319.1M as of June 30, 2024, up from $275.8M at Dec 31, 2023; runway into 2026.
Dosed first patients in Japanese cohort for hypothalamic obesity Phase 3 trial; top-line data from pivotal cohort expected 1H 2025.
Completed sNDA submission to FDA for IMCIVREE in children age 2-6; EC already expanded to age 2 in Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.